Quinupristin-dalfopristin combined with β-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 7, 2000, Pages 1789-1795

  Vouillamoz, J ^a   Entenza, J M ^a   Feger C ^b   Glauser, M P ^a   Moreillon, P ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; BETA LACTAM ANTIBIOTIC; CEFAMANDOLE; CEFEPIME; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; FLUCLOXACILLIN; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; LINCOSAMIDE DERIVATIVE; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOGRAMIN DERIVATIVE; TETRACYCLINE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; CEFAMANDOLE; CEPHALOSPORINS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; ENDOCARDITIS, BACTERIAL; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; RATS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS; VIRGINIAMYCIN;

EID: 0033933606     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.7.1789-1795.2000     Document Type: Article

References (26)

1. Amsterdam, D. 1996. Susceptibility testing of antimicrobials in liquid media, p. 52-111. In V. Lorian (ed.), Antibiotics in laboratory medicine. The Williams & Wilkins Co., Baltimore, Md.
2. Barbhaiya, R. H., S. T. Forgue, C. R. Gleason, C. A. Knupp, K. A. Pittman, D. J. Weidler, H. Movahhed, J. Tenney, and R. R. Martin. 1992. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob. Agents Chemother. 36:552-557.
3. Blanc, D. S., C. Pelignat, P. Moreillon, J. M. Entenza, M. C. Eisenring, H. Kleiber, A. Wenger, N. Troillet, C. H. Blanc, and P. Francioli. 1999. Unusual spread of a penicillin-susceptible methicillin-resistant Staphylococcus aureus clone in a geographic area of low incidence. Clin. Infect. Dis. 29:1512-1518.
4. Brumfitt, W., J. M. Hamilton-Miller, and S. Shah. 1992. In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria. J. Antimicrob. Chemother. 30(Suppl. A):29-37.
5. Chin, N. X., and H. C. Neu. 1992. Post-antibiotic effect of the new streptogramin RP 59500. Eur. J. Clin. Microbiol. Infect. Dis. 11:642-645.
6. Cocito, C., M. Di Giambattista, E. Nyssen, and P. Vannuffel. 1997. Inhibition of protein synthesis by streptogramins and related antibiotics. J. Antimicrob. Chemother. 39(Suppl. A):7-13.
7. Eliopoulos, G. M., and R. C. Moellering, Jr. 1996. Antimicrobial combinations, p. 330-396. In V. Lorian (ed.), Antibiotics in laboratory medicine. The Williams & Wilkins Co., Baltimore, Md.
8. Entenza, J., O. Marchetti, M. P. Glauser, and P. Moreillon. 1998. Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis. Antimicrob. Agents Chemother. 42:1889-1894.
9. Entenza, J. M., H. Drugeon, M. P. Glauser, and P. Moreillon. 1995. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrob. Agents Chemother. 39:1419-1424.
10. Etienne, S. D., G. Montay, A. Le Liboux, A. Frydman, and J. J. Garaud. 1992. A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500. J. Antimicrob. Chemother. 30(Suppl. A):123-131.
11. Fantin, B., R. Leclercq, L. Garry. and C. Carbon. 1997. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis. Antimicrob. Agents Chemother. 41:931-935.
12. Fantin, B., R. Leclercq, Y. Merle, L. Saint-Julien, C. Veyrat, J. Duval, and C. Carbon. 1995. Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob. Agents Chemother. 39:400-405.
13. Fantin, B., R. Leclercq, M. Ottaviani, J. M. Vallois, B. Maziere, J. Duval, J. J. Pocidalo, and C. Carbon. 1994. In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrob. Agents Chemother. 38:432-437.
14. Fass, R. J. 1991. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob. Agents Chemother. 35:553-559.
15. Finch, R. G. 1996. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use. Drugs 51(Suppl. 1):31-37.
16. Fluckiger, U., P. Francioli, J. Blaser, M. P. Glauser, and P. Moreillon. 1994. Role of amoxicillin serum levels for successful prophylaxis of experimental endocarditis due to tolerant streptococci. J. Infect. Dis. 169:1397-1400.
17. Heraief, E., M. P. Glauser, and L. R. Freedman. 1982. Natural history of aortic valve endocarditis in rats. Infect. Immun. 37:127-131.
18. Johnson, C. A., C. A. Taylor III, S. W. Zimmerman, W. E. Bridson, P. Chevalier, O. Pasquier, and R. I. Baybutt. 1999. Pharmacokinetics of quinupristin-dalfopristin in continuous ambulatory peritoneal dialysis patients. Antimicrob. Agents Chemother. 43:152-156.
19. Jones, R. N., C. H. Ballow, D. J. Biedenbach, J. A. Deinhart, and J. J. Schentag. 1998. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diag. Microbiol. Infect. Dis. 31:437-451.
20. Leclercq, R., L. Nantas, C. J. Soussy, and J. Duval. 1992. Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J. Antimicrob. Chemother. 30(Suppl. A):67-75.
21. Lorian, V., L. Amaral, and F. Fernandes. 1995. RP 59500 postantibiotic effect defined by bacterial ultrastructure. Drugs Exp. Clin. Res. 21:125-128.
22. Lorian, V., Y. Esanu, and L. Amaral. 1994. Ultrastructure alterations of Staphylococcus aureus exposed to RP59500. J. Antimicrob. Chemother. 33: 625-628.
23. Lorian, V., and F. Fernandes. 1999. Electron microscopy studies of the bactericidal effects of quinupristin/dalfopristin on Staphylococcus aureus. J. Antimicrob. Chemother. 43:845-848.
24. Que, Y. A., J. M. Entenza, P. Francioli, and P. Moreillon. 1998. The impact of penicillinase on cefamandole treatment and prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 177:146-154.
25. Scheel, O., D. J. Lyon, V. T. Rosdahl, F. A. Adeyemi-Doro, T. K. Ling, and A. F. Cheng. 1996. In-vitro susceptibility of isolates of methicillin-resistant Staphylococcus aureus 1988-1993. J. Antimicrob. Chemother. 37:243-251.
26. Sieradzki, K., and A. Tomasz. 1997. Suppression of beta-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics. J. Antimicrob. Chemother. 39(Suppl. A):47-51.